Intracellular pharmaceutical targeting
AssigneeChildren's Hospital Medical Center
InventorsMARC E. ROTHENBERG, NIVES ZIMMERMANN
Life of this patent
Estimating the term…
Abstract
A method and composition to target compounds into cells such as eosinophils. A ligand for a CCR-3 eosinophil surface receptor is provided under conditions to bind to the receptor and cause internalization of the ligand-CCR-3 complex. A compound, such as a drug in an active or inactive form, may be bound to the ligand and delivered to an intracellular site of the cell where it may subsequently become activated. The methods and compositions may be used to treat a variety of eosinophil-mediated disorders, for example, allergies.
Claims28
A method for intracellular targeting comprising providing a ligand for a CCR-3 surface receptor on a cell under conditions to form a ligand-receptor complex and internalizing said complex into said cell.
A composition for treating an eosinophil-mediated disorder comprising a ligand for a CCR-3 eosinophil receptor having a compound bound to said ligand in a pharmaceutically acceptable formulation.
A method to prevent eosinophilia comprising providing a ligand for a CCR-3 receptor on an eosinophil under conditions to form a ligand-receptor complex and internalizing said complex into said eosinophil.
A method to treat or protect against a human immunodeficiency virus (HIV) comprising providing a ligand in a pharmaceutically acceptable formulation for a CCR-3 cell surface receptor under conditions to form a ligand-CCR-3 complex and preventing said HIV binding to said CCR-3 by internalizing said ligand-CCR-3 complex.
A method for down-regulating a CCR-3 cell surface receptor comprising providing a ligand for said receptor under ligand-binding conditions, binding said ligand to said receptor and thereafter internalizing said receptor into said cell.
Dependencies are inferred from the claim text.